PGEN NASDAQ
Precigen, Inc.
1W: -9.3%
1M: -22.1%
3M: +9.2%
YTD: +41.1%
1Y: +42.1%
3Y: +464.5%
5Y: +28.0%
$6.15
+0.11 (+1.82%)
After Hours: $6.17 (+0.02, +0.41%)
Weekly Expected Move ±9.8%
$5
$6
$6
$7
$7
Credit Risk of going bust: higher than 53% of companies Debt: 4.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.3%), Precigen, Inc. would be worth roughly what it owes.
Total debt $98.3M against a stock market value of $2.16B.
Distance to default 4.81 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $46.9M (short-term plus half of long-term), stock volatility 76.7%; Altman Z'' -46.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.3%), Precigen, Inc. would be worth roughly what it owes.
Total debt $98.3M against a stock market value of $2.16B.
Distance to default 4.81 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $46.9M (short-term plus half of long-term), stock volatility 76.7%; Altman Z'' -46.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Precigen, Inc. $PGEN Stock Sold by Iridian Asset Management LLC CT
Precigen, Inc. (NASDAQ:PGEN) Stock Has Average Price Target of $13.67
(PGEN) Volatility Zones as Tactical Triggers - Stock Traders Daily
PGEN Apr 2027 11.000 call (PGEN270416C00011000) Stock Price, News, Quote & History - Yahoo! Finance Canada
Precigen Inc Actuals & Estimates (NASDAQ:PGEN) - TradingView
Precigen, Inc. (PGEN) stock price, news, quote and history - Yahoo Finance UK
Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis
Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis - Yahoo Finance
PGEN Nov 2026 10.000 call (PGEN261120C00010000) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada
PGEN Nov 2026 10.000 call (PGEN261120C00010000) Interactive Stock Chart - Yahoo! Finance Canada
$PGEN stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
These healthcare stocks stand out with A+ growth grades
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know - Yahoo Finance
Why Did Precigen (PGEN) Stock Climb After Its Latest Update? - Simply Wall Street
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
uniQure Plunges on Additional Data From Huntington's Disease Study
uniQure Plunges on Additional Data From Huntington's Disease Study
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Here's Why You Should Add URGN Stock to Your Portfolio Now
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Yahoo Finance
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN
Precigen (NASDAQ:PGEN) Shares Gap Up After Analyst Upgrade
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap? - Yahoo Finance
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today? - Stocktwits
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today? - Yahoo Finance
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Vertex Posts Positive Phase II Data on Kidney Disease Drug
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Precigen (NASDAQ:PGEN) Hits New 1-Year High – Time to Buy?
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
Precigen (NASDAQ:PGEN) Hits New 52-Week High – What’s Next?
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base - Yahoo Finance
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Definium Reports Second Phase III Success in Anxiety Disorder Program
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
Legal & General Group Plc Takes $730,000 Position in Precigen, Inc. $PGEN
Jupiter Topco LLC Makes New Investment in Precigen, Inc. $PGEN